

HEALTHTECH IN MOTION

28 INTERNATIONAL STARTUPS
WITH BELARUSIAN ROOTS

PRODUCTS / FOUNDERS / FUNDING / EVIDENCE

PEOPLE
IDEAS
GLOBAL
IMPACT

Partner perspective

WHY THIS RESEARCH MATTERS

“

We see founders with Belarusian roots building companies across different markets, but this activity is difficult to see as one ecosystem. Research like this helps make the pattern visible: where new companies are emerging, what they are building, and how their paths differ across markets. For investors and ecosystem players, that visibility matters.

That is why DÕBRA partnered with BYGRID on this research.



AJ Skrabowski

Founder,
DÕBRA Impact Venture Studio

A New HealthTech Wave Is Taking Shape

THE BIG FINDING

50%

founded in
2023–2025

75%

based in
Europe

75%

founded by experienced
entrepreneurs

79%

target
global markets

The pattern suggests not simply relocation, but the formation of a new generation of globally oriented companies with Belarusian roots, built by founders with prior entrepreneurial experience.

Research Methodology

HOW THE SAMPLE WAS BUILT AND THE DATA WAS VERIFIED

■ INCLUSION CRITERIA

The study included international HealthTech startups meeting the following criteria:

- at least one founder has Belarusian roots;
- the project showed signs of activity within the past 6 months: product development, fundraising, participation in industry programs and events, or other public updates;
- the project's core operations are based outside Belarus: through its team, markets, customers, partnerships, fundraising, or other operational ties;
- the product has reached at least a working MVP stage and shows evidence of use or testing beyond the founding team.

■ WHAT WE MEAN BY HEALTHTECH

HealthTech is used as an umbrella category for technologies and digital products that address specific physical or mental health needs.

This includes products related to prevention, diagnostics, treatment, condition monitoring, healthcare delivery, and health management.

Products focused primarily on productivity, habit-building, time management, or general wellbeing without a specific health-related purpose were not included in the sample.

■ SOURCES AND VERIFICATION

Data was collected from public sources: company websites, startup and deal databases, media publications, announcements from investors and accelerators, research publications, and other public materials. AI tools, including ChatGPT, Perplexity, and Grok, were used to search for and initially organize information.

Key point: AI was used for searching and processing information, not as an independent data source. Data on fundraising, research, clinical validation, and regulatory status was verified against primary or independent public sources.

Research Limitations

WHAT MATTERS WHEN INTERPRETING THE RESULTS

■ KEY LIMITATION

The sample is not exhaustive.

There is no comprehensive public record of international startups with Belarusian roots. The study includes projects that could be identified and verified through publicly available information and contributions from ecosystem participants.

■ RESEARCH SNAPSHOT

This research provides a snapshot of international HealthTech startups with Belarusian roots, based on publicly available information about their products, markets, teams, funding, and public signals of research, clinical, or regulatory development.

The study represents a snapshot of the ecosystem as of September 2026, not a registry of all existing projects. The composition of the sample and individual figures may be refined as new confirmed information becomes available.

■ DISCOVERY BIAS

The sample may not include non-public projects and companies with a limited digital footprint.

■ FUNDING DATA

Only deals and amounts that could be confirmed through public sources were included. Accordingly, the disclosed investment volume should be interpreted as a confirmed minimum, not an estimate of total capital raised.

■ DYNAMIC DATA

Company status, team size, investment, and other metrics change over time. The data reflects information available at the time of the study (July–August 2026).

THE FOLLOWING CONTRIBUTED TO SOURCING
AND VERIFYING PROJECTS:

DÖBRA Venture Studio, Angels Band, and Axios.

International HealthTech Startups with Belarusian Roots

28 ACTIVE PROJECTS IN RESEARCH SAMPLE

 Anticipate	 Bear Room	 Body Bloom AI	 Carrot Care	 CleverPoint	 DeeDee	 DIAQNOSTIC
 Doctorina	 Flo Health	 Goodville	 Healsens	 Heartery	 HeartScan	 MamaAir.Africa
 MEDvidi	 Melloway	 OpenHalt	 MindMuscle (ex-PigPug)	 Skinive	 Soula	 Stork
 Thera	 Voka	 VR Neurolink AI	 WLLNSS	 Yummday	 Zing Coach	 Zomni

CURRENT SNAPSHOT

The study includes 28 HealthTech startups that met the activity criteria at the time the data was recorded. Four additional projects identified during the research were inactive and therefore excluded from the current sample.

A New Wave, Distributed Geography, Experienced Founders

WHEN COMPANIES WERE FOUNDED, WHERE THEY'RE BASED, HOW BIG THEY ARE, AND WHO'S BUILDING THEM




50%

FOUNDED IN
2023-2025

WHEN THEY WERE FOUNDED

14 of 28 projects were founded in 2023-2025. 2024 was the peak year, with 9 new companies.

NUMBER OF STARTUPS BY YEAR FOUNDED



75%

BASED
IN EUROPE

WHERE THEY'RE BASED

21 of 28 projects (75%) are located in Europe. The largest hub is Poland: 8 companies, or 28.6% of the sample.

COMPANIES BY COUNTRY



Location is determined by the company's current LinkedIn profile; it could not be determined for 2 projects.




75%

TEAMS OF UP
TO 10 PEOPLE

TEAM SIZE

21 of 28 companies (75%) have a team of up to 10 people. Another 4 have 11-50 people; only 3 companies have more than 50 employees.



Team size is determined based on the company's LinkedIn profile; used as an approximate scale estimate, not an exact headcount.



75%

EXPERIENCED
FOUNDERS

FOUNDER EXPERIENCE

75% of projects were launched by experienced entrepreneurs.

In 21 of 28 companies, at least one founder has previously launched a startup or run their own business.

Different Problems, a Global Market, and a Bet on the End User

WHAT HEALTHTECH STARTUPS WITH BELARUSIAN ROOTS DO, WHO THEY SELL TO, AND WHAT GEOGRAPHY THEY TARGET


WHAT THEY DO

Projects address very different needs — from heart rate and blood pressure monitoring, to skin change assessment, to support for anxiety, ADHD, pregnancy, sleep, and eating issues.

	Diagnostics & Monitoring	6 (21.4%)
	Mental Health & Emotional Wellbeing	6 (21.4%)
	Women's & Family Health	5 (17.9%)
	Biomarkers & Longevity	4 (14.3%)
	Cognitive Health	3 (10.7%)
	Nutrition, Fitness & Sleep	3 (10.7%)
	Healthcare Infrastructure	1 (3.6%)

There is no single dominant category. The two largest segments — diagnostics & monitoring, and mental health & emotional wellbeing — each account for 21.4% of the sample.


WHO THEY SELL TO



- B2C only — 46% / 13 projects**
Products for end users only
- B2C + B2B or B2B2C — 36% / 10 projects**
Combine work with users and organizations
- B2B only — 18% / 5 projects**
Focused on organizations

Half the sample works only with end users, but nearly a third of projects also have an institutional component. Work with organizations takes different forms — from products for doctors and employers to API integrations and pilots with clinics.

WHERE THEY SELL



- Global — 79% / 22 projects**
- Regional / single-country — 18% / 5 projects**
- Could not be determined — 3% / 1 project**

Despite most companies being based in Europe, 79% focus on the global market.

AI Is Widespread — Evidence Takes Different Forms


AI USE AND PUBLIC SIGNALS OF RESEARCH, CLINICAL, REGULATORY AND TECHNOLOGICAL DEVELOPMENT

■ AI USE

71%

20 of 28 startups

AI confirmed either through direct company mentions or other public sources.



■ PUBLIC SIGNALS OF MATURITY

		STARTUPS	SHARE
	Product research trail	6 of 28	21%
	Claimed clinical validation	3 of 28	11%
	Independent academic trail	4 of 28	14%
	Regulatory status / process	2 of 28	7%
	ISO / patents	3 of 28	11%

 **16 of 28** none of these public signals were found

At least one of the public signals tracked in this study was found for 12 of 28 startups (43%).

The type and relevance of these signals vary substantially by product and stage.

These signals are not a quality scale and should not be compared directly. Their relevance depends on the product: not every HealthTech solution requires clinical validation or medical device status, while ISO certification and patents do not demonstrate clinical effectiveness. The study captures only publicly discoverable data.

There's a New Wave — but No Big Rounds Yet

HEALTHTECH FUNDING WITH BELARUSIAN ROOTS IN 2023–2025 • LITHUANIA AS A BENCHMARK

HEALTHTECH WITH BELARUSIAN ROOTS

PRE-SEED / SEED • 2023–2025


7	13	\$2.296M + €0.76M
startups	funding events	disclosed amount**

FUNDING BY YEAR

2023

3 events • \$0.701M


Soula × 3



2024

8 events • \$1.095M + €0.5M

Soula × 4, Thera, DÖBRA, CleverPoint, Heartery



2025

2 events • \$0.5M + €0.26M

MindMuscle (ex-PigPug), Doctorina



3 of 7 funded startups were founded in 2023–2025.

LITHUANIAN HEALTHTECH


PRE-SEED / SEED / SERIES A • 2023–2025

9	9	≥€29.2M
startups	deals	total amount

FUNDING BY YEAR


2023

2 deals • €10.4M




2024

3 deals • €12.7M



2025

4 deals • €6.6M



The largest checks — €3–6.5M — go to projects in medical AI, biotech, robotics, and neurotechnology.

At least two startups plan to allocate part of the raised funds toward CE/MDR certification.

HealthTech with Belarusian roots is still at an early stage: half of the active sample was founded in 2023–2025, and funding remains concentrated in a few companies. **Lithuania is used as a regional benchmark:** a nearby European ecosystem with an established HealthTech and life-sciences funding infrastructure.

Key Findings

WHAT THE 28-COMPANY SAMPLE SHOWS



01

A new wave is visible.

Half of the active sample was founded since 2023, suggesting renewed company formation rather than only the continuation of older Belarusian-founded businesses.



02

The ecosystem is distributed rather than relocated.

Companies are concentrated in Europe but spread across multiple hubs and mostly target global markets.



03

Experienced founders are building lean companies.

Small teams dominate, while three quarters of projects have founders with previous entrepreneurial experience.



04

Software and AI scale faster than formal evidence.

AI is already widespread, while publicly visible research, clinical, regulatory and technological maturity varies substantially.



05

The wave is visible before the capital is.

New companies and funding events are appearing, but publicly disclosed rounds remain small and concentrated.

What comes next

THIS RESEARCH IS A FIRST SNAPSHOT OF A CHANGING ECOSYSTEM.
WE WILL CONTINUE COVERING ITS DEVELOPMENT THROUGH RESEARCH, NEWS, AND FOUNDER STORIES.



COMPANIES

new products and emerging projects



PRODUCTS

research, technology, and product development



ECOSYSTEMS

market trends and lessons from different startup environments

Follow BYGRID →

BYGRID.IO

Research & media partnerships →

jn@bygrid.io

BYGRID turns scattered public information into editorial context.

PEOPLE
IDEAS
GLOBAL
IMPACT